These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39396065)

  • 21. Acetylation of tau inhibits its degradation and contributes to tauopathy.
    Min SW; Cho SH; Zhou Y; Schroeder S; Haroutunian V; Seeley WW; Huang EJ; Shen Y; Masliah E; Mukherjee C; Meyers D; Cole PA; Ott M; Gan L
    Neuron; 2010 Sep; 67(6):953-66. PubMed ID: 20869593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo.
    Gorsky MK; Burnouf S; Dols J; Mandelkow E; Partridge L
    Sci Rep; 2016 Mar; 6():22685. PubMed ID: 26940749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylated tau in Alzheimer's disease: An instigator of synaptic dysfunction underlying memory loss: Increased levels of acetylated tau blocks the postsynaptic signaling required for plasticity and promotes memory deficits associated with tauopathy.
    Tracy TE; Gan L
    Bioessays; 2017 Apr; 39(4):. PubMed ID: 28083916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy.
    Zhang D; Zhang W; Ming C; Gao X; Yuan H; Lin X; Mao X; Wang C; Guo X; Du Y; Shao L; Yang R; Lin Z; Wu X; Huang TY; Wang Z; Zhang YW; Xu H; Zhao Y
    Neuron; 2024 May; 112(10):1676-1693.e12. PubMed ID: 38513667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau exhibits unique seeding properties in globular glial tauopathy.
    Chung DC; Carlomagno Y; Cook CN; Jansen-West K; Daughrity L; Lewis-Tuffin LJ; Castanedes-Casey M; DeTure M; Dickson DW; Petrucelli L
    Acta Neuropathol Commun; 2019 Mar; 7(1):36. PubMed ID: 30845985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States.
    Haj-Yahya M; Lashuel HA
    J Am Chem Soc; 2018 May; 140(21):6611-6621. PubMed ID: 29684271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
    Combs B; Hamel C; Kanaan NM
    Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
    Vingtdeux V; Davies P; Dickson DW; Marambaud P
    Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains.
    Nagamine S; Yamazaki T; Makioka K; Fujita Y; Ikeda M; Takatama M; Okamoto K; Yokoo H; Ikeda Y
    Neuropathology; 2016 Aug; 36(4):333-45. PubMed ID: 26685795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assembly of filamentous tau aggregates in human neuronal cells.
    Ko LW; Rush T; Sahara N; Kersh JS; Easson C; Deture M; Lin WL; Connor YD; Yen SH
    J Alzheimers Dis; 2004 Dec; 6(6):605-22; discussion 673-81. PubMed ID: 15665401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
    Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
    Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A validated antibody panel for the characterization of tau post-translational modifications.
    Ercan E; Eid S; Weber C; Kowalski A; Bichmann M; Behrendt A; Matthes F; Krauss S; Reinhardt P; Fulle S; Ehrnhoefer DE
    Mol Neurodegener; 2017 Nov; 12(1):87. PubMed ID: 29157277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation.
    Ajit D; Trzeciakiewicz H; Tseng JH; Wander CM; Chen Y; Ajit A; King DP; Cohen TJ
    J Biol Chem; 2019 Nov; 294(45):16698-16711. PubMed ID: 31543505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer's Disease and Primary Tauopathy Postmortem Brains.
    Helboe L; Rosenqvist N; Volbracht C; Pedersen LØ; Pedersen JT; Christensen S; Egebjerg J; Christoffersen CT; Bang-Andersen B; Beach TG; Serrano GE; Falsig J
    J Alzheimers Dis; 2022; 88(1):207-228. PubMed ID: 35570492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
    Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
    PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing acetylated tau is neuroprotective in brain injury.
    Shin MK; Vázquez-Rosa E; Koh Y; Dhar M; Chaubey K; Cintrón-Pérez CJ; Barker S; Miller E; Franke K; Noterman MF; Seth D; Allen RS; Motz CT; Rao SR; Skelton LA; Pardue MT; Fliesler SJ; Wang C; Tracy TE; Gan L; Liebl DJ; Savarraj JPJ; Torres GL; Ahnstedt H; McCullough LD; Kitagawa RS; Choi HA; Zhang P; Hou Y; Chiang CW; Li L; Ortiz F; Kilgore JA; Williams NS; Whitehair VC; Gefen T; Flanagan ME; Stamler JS; Jain MK; Kraus A; Cheng F; Reynolds JD; Pieper AA
    Cell; 2021 May; 184(10):2715-2732.e23. PubMed ID: 33852912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models.
    Choi H; Kim HJ; Yang J; Chae S; Lee W; Chung S; Kim J; Choi H; Song H; Lee CK; Jun JH; Lee YJ; Lee K; Kim S; Sim HR; Choi YI; Ryu KH; Park JC; Lee D; Han SH; Hwang D; Kyung J; Mook-Jung I
    Aging Cell; 2020 Jan; 19(1):e13081. PubMed ID: 31763743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.
    Serrano-Pozo A; William CM; Ferrer I; Uro-Coste E; Delisle MB; Maurage CA; Hock C; Nitsch RM; Masliah E; Growdon JH; Frosch MP; Hyman BT
    Brain; 2010 May; 133(Pt 5):1312-27. PubMed ID: 20360050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
    Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
    J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.